About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corp (NY: GKOS )

131.96 +4.10 (+3.21%)
Streaming Delayed Price Updated: 10:52 AM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corp

< Previous 1 2 3 4 5 6 7 8 Next >
What 10 Analyst Ratings Have To Say About Glaukos
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
Via Benzinga
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE). 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Via Benzinga
7 Analysts Have This to Say About Glaukos
Via Benzinga
Analyst Ratings for Glaukos
Via Benzinga
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Where Glaukos Stands With Analysts
Via Benzinga
What 4 Analyst Ratings Have To Say About Glaukos
Analysts have provided the following ratings for Glaukos (NYSE:GKOS) within the last quarter: 
Via Benzinga
Needham Says Recent Launches To Drive Market Share Recovery For This Eye-Focused MedTech Stock
Via Benzinga
Glaukos Announces Participation in the Stephens Annual Investment Conference
From Glaukos Corporation
Via Business Wire
Kellogg, Palo Alto Networks, Roku And Other Big Losers From Thursday
U.S. stocks closed lower on Thursday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Glaukos Corporation Announces Third Quarter 2022 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Shares Pop After Positive Data From Ocular Pressure Candidate
Via Benzinga
Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment
Via Benzinga
Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2
From Glaukos Corporation
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
Via Benzinga
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Dow Jumps 450 Points; UiPath Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones adding around 450 points on Wednesday. 
Via Benzinga
Dow Up 249 Points, Nasdaq Set To Snap Skid
Stocks are charging higher this afternoon, though investors are still awaiting the release of the Federal Reserve's Beige Book. 
Via Talk Markets
Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy. 
Via Benzinga
Coupa Software, Glaukos And Some Other Big Stocks Moving Higher On Wednesday
  
Via Benzinga
What's Going On With Glaukos Shares?
Glaukos Corp (NYSE: GKOS) shares are trading higher by 1.87% to $49.00 Wednesday morning after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved... 
Via Benzinga
Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles
From Glaukos Corporation
Via Business Wire
Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
Glaukos Stock Scores Rising Price Performance With Jump To 91 RS Rating
On Tuesday, Glaukos stock hit an key technical milestone, with its Relative Strength Rating climbing to 91, up from 87 the day before. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.